Fig. 8From: Immune classifier-based signatures provide good prognostic stratification and predict the clinical benefits of immune-based therapies for hepatocellular carcinomaPotential therapeutic drugs for Group 4 based on T cell expression. a Group 4 had a higher level of T cell dysfunction than the other subgroups. b–s Eighteen drugs with obvious differences in sensitivity in Group 4. These results indicate that Group 4 is more sensitive to EHT 1864, FH535, and lapatinib chemotherapy than the other groupsBack to article page